| Name | Title | Contact Details |
|---|
Fundamentally we exist for one reason: To be the trusted solution for our clients as they strive to build a better working world and improve the human experience. We are 550+ global experts that bring top-tier expertise to every stage of a project, from creating comprehensive, detailed project plans to eliminating that last punch list item and beyond, into rigorous asset management, reliability, and sustainability activities. We are your choice regardless of your location. We can support you in the US, Singapore, China, Australia, Europe, Korea, Malaysia, Vietnam and beyond. Philosophically and practically, we believe that quality, cost, and schedule can be mutually reinforcing – trade-offs are not necessary. Short-changing the focus on quality usually means problems down the road – problems that can cost money and delay the schedule. But if quality is built in from the start, then both project delivery and operational efficiency can be achieved with a much higher degree of assurance. When your project requires planned, managed, and documented high quality to exacting global standards. When you need high-performance teams on mission-critical projects. When your project is complex, high-visibility, and carries significant risk. We can help you meet a higher standard.
Clinical DataFax Systems, Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QoL Meds is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"